On August 31, INSILICO fell 5.27% in regular trading, trading at HK$43.86 per share, with turnover of HK$133 million, extending its recent downward trend.

On the news front, the company signed a subscription agreement with Deutsche Bank AG, Hong Kong Branch on August 27 to issue zero-coupon convertible bonds due in 2027 with an aggregate principal amount of US$305 million. The initial conversion price was set at HK$58.07 per share, representing a premium of approximately 23.5% over the closing price of HK$47.02 on the signing date and approximately 32.9% above the five-day average closing price of HK$43.70. If fully converted, approximately 41.17 million new shares would be issued, representing about 7.07% of the existing issued share capital. The potential equity dilution effect has triggered selling pressure in the market. Net proceeds after deducting underwriting commissions and related expenses are estimated at approximately US$301.6 million.

Within the Life Sciences Tools & Services sector, the broader group also traded lower. Among peers, XTALPI fell 3.88%, WUXI BIO fell 3.65%, GENSCRIPT BIO fell 3.14%, WUXI APPTEC fell 2.94%, and WUXI XDC fell 2.72%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)